. Author manuscript; available in PMC: 2009 Aug 14.

Published in final edited form as: Cancer Control. 2008 Oct;15(Suppl):40–49. doi: 10.1177/107327480801504s05

Table 2.

Azacitidine: Overall Survival Data

Group	% Patients	Median Overall Survival (mos)		HR (95% CI)	Log-Rank P
Group	% Patients	AZA	CCR	HR (95% CI)	Log-Rank P
Good	46	Not reached	17.1	0.61 (0.39, 0.96)	.030
Intermediate	21	26.3	17.0	0.43 (0.21, 0.88)	.017
Poor	28	17.2	6.0	0.52 (0.32, 0.87)	.011

This research was originally published in Blood. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007;110:250a. Abstract 817. © American Society of Hematology. Reprinted with permission.